Bayesian individual exposure estimation of dabrafenib alone or in combination with trametinib in mutated-BRAF V600E metastatic melanoma patients.

Lauriane Goldwirt,Claire Pressiat,I. Chami,Vincent Jullien,H Sauvageon,Isabelle Madelaine,Celeste Lebbe,Samia Mourah

Bayesian individual exposure estimation of dabrafenib alone or in combination with trametinib in mutated-BRAF V600E metastatic melanoma patients.

2016

Lauriane Goldwirt
Claire Pressiat
I. Chami
Vincent Jullien
H Sauvageon
Isabelle Madelaine
Celeste Lebbe
Samia Mourah

e14105Background: Dabrafenib (DAB) has clinical activity with a manageable safety profile in mutated-BRAF(V600E) metastatic melanoma patients (MMP). However, resistance to therapy with BRAF kinase ...

Keywords:

Melanoma
Trametinib
Oncology
Pathology
Dabrafenib
BRAF V600E
Medicine
Internal medicine
metastatic melanoma
V600E
safety profile

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations